{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088346","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.430880+00:00","generated_at":"2026-06-12T04:17:59.423832+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theravance Biopharma Q2 2023: YUPELRI sales up 12% YoY; $80.5M in share buybacks","bullets":["YUPELRI net sales recognized by Viatris: $55.0M, up 12% YoY; Theravance's 35% share implies $19.3M.","YUPELRI retail TRx and new-to-product TRx hit all-time highs, up 26% and 53% YoY (Symphony Health).","PIFR-2 enrollment nearing completion; top-line data late Q4 2023, disclosure expected Jan 2024.","$80.5M share repurchases in Q2 2023 ($263.8M cumulative); $61.2M remaining in $325M program to complete by year-end.","TRELEGY ELLIPTA Q2 global net sales $760M (+29% YoY); $50M milestone from Royalty Pharma if 2023 sales ≥ $2.9B."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088346","json":"https://secwatch.observer/filing/0001104659-23-088346.json","markdown":"https://secwatch.observer/filing/0001104659-23-088346.md","text":"https://secwatch.observer/filing/0001104659-23-088346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923088346/0001104659-23-088346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923088346/tm2322953d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:17:59.423832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}